INSIGHT BANK · 28 LIVING CARDS
Follow a question.
See what changes.
Evidence, technologies, people and the next test—connected, but not confused.
Commercializationv1 · 10.19
How much can easier administration contribute to treatment initiation and drug sales in thyroid eye disease?
The US approved Enspryng for adult thyroid eye disease. SatraGO-2 met its primary endpoint, whereas SatraGO-1 did not. Maintenance dosing is a subcutaneous injection every four weeks, with home administration possible after training.
- ✓New US indication approvedRecorded
- ?Track patient uptakeUnverified
- ?Compare indication-specific salesUnverified
New question openedRecord the new indication, the two trial outcomes and the administration route, and begin tracking uptake and indication-specific sales.
NEXT CHECKFollow disclosed new treatment starts, switches from other therapies and indication-specific sales in thyroid eye disease, separately from total Enspryng revenue.
Frontier Sciencev1 · 10.19
Which conditions separate placental and fetal outcomes after the same maternal immune challenge?
Within 24 hours of immune stimulation in mice, developmental abnormalities were reported in roughly 30% of fetuses, limited to a subset of males. Affected fetuses also showed placental inflammatory changes, structural disruption and immune-cell and cytokine accumulation in amniotic fluid.
- ✓Acute heterogeneity observedRecorded
- ?Test the role of local conditionsUnverified
- ?Connect to longer-term developmentUnverified
New question openedSeparate the ASD research context, current acute findings and earlier placental IL-6 intervention, and add the question of local environment.
NEXT CHECKResearch separating placental inflammatory regulation, structural maintenance and developmental timing, and testing whether changing local conditions alters fetal outcomes.